Foundation Series - Article 2 of 5
Execution — not access — is the bottleneck. The Hub treats cross-cultural literacy as a practical capability that determines whether international collaboration is safe, scalable, and sustainable.
Innovation travels easily in theory. A promising technology, encouraging early evidence, and an appetite to scale. In practice, many innovations falter not because they lack quality — but because they are asked to perform in healthcare systems with different regulatory logics, procurement incentives, clinical workflows, and evidence expectations.
The problem is rarely access. It is execution.
For organisations working across the UK and Chinese systems, the distinction matters. Both are large and clinically sophisticated, yet they operate under different constraints and priorities. Treating them as interchangeable introduces clinical, operational, and reputational risk. Cross-cultural literacy is what prevents that from happening — and the Hub treats it as a core, practical execution capability, not a soft add-on.
From Proof to Practice
Early-stage innovation is optimised for proof: demonstration that a technology works in a defined setting. System maturity changes the question. What matters next is not whether something can work — but whether it can work reliably, reproducibly, and safely at scale.
As systems mature, evidence thresholds rise, post-market performance becomes visible, and lifecycle governance moves to the centre of adoption decisions. In the UK, adoption is shaped by integrated care pathways, commissioning logic, value-assessment, and workforce realities. In China, clinical execution is shaped by hospital stratification, procurement mechanisms, regulatory sequencing, and rapid standardisation across large delivery environments.
Neither system is ‘ahead’ of the other. They are different — and those differences affect how innovations must be designed and governed.
When execution fails, it is usually a shared-understanding problem
Clinical execution is made, not assumed. Manufacturing quality, supply-chain resilience, training infrastructure, service support, and post-market surveillance all influence whether clinicians and institutions can rely on a new intervention.
When execution fails, it is often because the practical arrangements that underpin safety and reliability were not aligned with system realities. What looks like a delivery problem is frequently a shared-understanding problem: unclear decision rights, divergent evidence expectations, and escalation pathways that exist on paper but do not function in practice.
Three levels of cross-cultural capability
Cross-cultural literacy develops in stages. The Hub finds it useful to think of three levels:
Level 1 — Awareness. Organisations recognise that governance, social organisation, and value systems differ. This basic awareness helps avoid repeatable mistakes: misreading regulatory sequencing, underestimating clinical accountability, or importing business models that do not map onto local procurement.
Level 2 — Practice. Organisations move beyond individual experience to codify what works: frameworks for earning clinical trust, pilot designs that withstand scrutiny, and responses when non-government actors raise concerns. Capability becomes organisational rather than personal.
Level 3 — Design. The most mature actors go further — co-creating new models: shared evidence frameworks, co-designed regulatory science pilots, and cross-border service models that draw on complementary strengths. This stage requires demonstrated governance maturity on both sides.
Most collaborations underestimate how long it takes to move from Level 1 to Level 2. The Hub’s role is to help organisations make that journey deliberately, not accidentally.
What this means for the Hub's approach
The Hub does not treat cross-cultural literacy as a background credential or a pre-departure training module. It is embedded in how readiness is assessed, how programme content is designed, and how facilitators are selected.
Organisations that can demonstrate cross-cultural capability at Level 2 or above — in practice, not just in principle — are better placed to carry the consequence of cross-border collaboration. This is part of what the IN2UK qualification process is designed to surface.
About the EFEC UK–China Life Sciences Innovation Hub
The EFEC UK–China Life Sciences Innovation Hub is an initiative of Excellence First Enterprise Consultancy (EFEC). The Hub is being developed as a governance-led trust infrastructure supporting
responsible collaboration across the UK and Chinese life sciences ecosystems. Its approach centres on a qualification-before connection model, designed to ensure that cross-system collaboration is built on evidence of execution readiness, governance maturity and shared professional standards.
The Hub is currently in Phase 1 development (2026), during which EFEC is articulating the
governance principles and operational frameworks that will underpin its future work. Insights from the Hub’s development are published periodically through the Foundation Series.
Disclaimer
This article reflects EFEC’s analysis and does not represent the official position of any institution referenced.
